ADCs: A Deeper Look at Antibody-Drug Conjugates and Why CMC Preparedness Is Everything

Last week we touched on ADC manufacturing complexity and why integrated CMC thinking matters. This week we want to go deeper and explore the ADC economy further.

ADCs are reshaping oncology as a significant change in how we approach targeted cancer therapy. What makes them scientifically compelling is precisely what makes their development operationally unforgiving.

What is an ADC: An ADC combines an antibody that homes in on a tumor-specific antigen, a chemical linker engineered to remain stable in circulation, and an ultrapotent cytotoxic payload released only after internalization by the target cell. Payloads are typically 100 to 1,000 times more toxic than conventional chemotherapy, delivered with a precision that systemic treatment cannot match.

ADCs Are Dominating Oncology: The global ADC market reached $13.5 billion in 2025, with 15 FDA-approved products and more than 400 programs in development. Enhertu alone generated $3.75 billion. Analysts project the market at $28 to $39 billion by 2034-2035. 

The deal landscape reflects this development with BioNTech committing up to $7.6 billion in milestones for a single ADC collaboration with Bristol Myers Squibb. Eli Lilly committed $5 billion to dedicated ADC manufacturing infrastructure. Boehringer Ingelheim paid $1.3 billion for platform company Synaffix.

Several factors are driving this development. Broad clinical validation with ADCs having shown efficacy across breast, lung, urothelial, gastric, and hematologic cancers. Enhertu's expansion into HER2-low and HER2-ultralow disease added an estimated 200,000 treatable patients in the U.S. with a single regulatory action. And Padcev plus Keytruda reduced mortality risk by 49% in urothelial cancer. Furthermore, there are three generations of improvement: Early ADCs (Mylotarg, Kadcyla) established proof of concept. Each subsequent generation brought better linker chemistry, antigen selection, and conjugation control. Third-generation molecules with site-specific conjugation and novel payloads have reset expectations for what targeted oncology can achieve.

All these developments allow for an expanding target landscape: HER2 remains dominant commercially, but the pipeline has broadened rapidly to TROP2, HER3, B7-H3, CLDN18.2, Nectin-4, and ROR1. Bispecific ADCs targeting dual antigens are entering phase III as a strategy against resistance. Lastly, in the combination with immunotherapy, ADCs can be paired with checkpoint inhibitors, showing synergistic activity across multiple tumor types, pulling the modality into earlier treatment lines and expanding its commercial reach.

CMC Preparedness Is Key

ADCs carry the full regulatory and manufacturing complexity of both a biologic and a small molecule, plus a third layer: conjugation chemistry that neither traditional CMC framework was designed to address.

The antibody intermediate requires cell line development, upstream process control, protein A purification, viral clearance validation, and glycan and charge variant analysis. 

The linker-payload must meet HPAPI containment standards, often at occupational exposure limits measured in nanograms per cubic meter of air and must be independently validated before conjugation begins.

The essential step of conjugation compounds the complexities mentioned above. The drug-to-antibody ratio (DAR) governs clearance rate, efficacy, aggregation, and toxicity. Because DAR is a distribution, not a single value, controlling it across batches, clinical phases, and manufacturing sites requires conjugation chemistry that is well-characterized from the earliest stages of development.

Analytical requirements follow: DAR demands mass spectrometry, free payload requires orthogonal chromatography, aggregation needs SEC-MALS or DLS, conjugation site heterogeneity requires peptide mapping. No single method is sufficient, and the Module 3 documentation burden for an ADC IND or BLA is substantially greater than for either an antibody or a small molecule alone.

The efforts necessary to satisfy the requirements during manufacturing of ADCs result in significant regulatory stakes. FDA data shows 11 of 32 Complete Response Letters for biologic programs were attributed to CMC deficiencies. ADCs sit at the intersection of biologic and small molecule frameworks, with no ADC-specific CMC guideline from FDA or EMA. Programs that treat the three workstreams as independent, or that engage regulators late, tend to encounter that ambiguity at IND review, at End of Phase 2, or in a CRL.

The result of these challenges is that ADC CMC timelines tend to be structurally longer. While stability studies run in real time, GMP scale-up requires process characterization that cannot be compressed. HPAPI linker-payload supply chains have limited sourcing options and long lead times, requiring commitments well ahead of clinical demand.

Programs that treat CMC as a Phase 2 problem consistently find that it becomes a Phase 3 crisis.

This is where Pharmefex comes in:

Our team includes specialists with hands-on experience in antibody development, ADC process development, and lipid nanoparticle systems. We think in the hybrid framework ADC programs require, across both the biologic and small molecule sides of the equation.

Our integrated oversight model covers scheduling, logistics, and quality across antibody production, linker-payload synthesis, and conjugation as a single workflow. When an upstream raw material changes, we assess downstream impact before implementation, maintaining consistency as programs scale.

We support colocation of antibody production, linker-payload synthesis, and conjugation, reducing inter-site transfer risks and keeping quality management unified across development stages. For programs moving toward IND and beyond, this coordination is where timelines are protected.

In summary: The challenge for drug development teams is whether their program is structured to get the molecule to patients, on time, with a regulatory package that holds up. That is the question Pharmefex is built to help answer and where Pharmefex adds value.

Sources

1. Drug Discovery News — What are antibody-drug conjugates (ADCs)? Mechanism, pipeline, and outlook (2025): https://www.drugdiscoverynews.com/what-are-antibody-drug-conjugates-adcs-mechanism-pipeline-and-outlook-16778

2. PMC / Frontiers in Oncology — Antibody–drug conjugate: a newly developed biological missile for tumor treatment (2025): https://pmc.ncbi.nlm.nih.gov/articles/PMC12605357/

3. PMC — The next frontier in antibody-drug conjugates: challenges and opportunities (2025): https://pmc.ncbi.nlm.nih.gov/articles/PMC12366496/

4. Biopharma PEG — ADC Market 2025: Rising Sales and Growing Phase III Pipelines (2025): https://www.biochempeg.com/article/447.html

5. Vision Lifesciences — ADC Market 2026: Antibody-Drug Conjugate Pipeline & Deals: https://visionlifesciences.com/insights/adc-antibody-drug-conjugate-market-licensing

6. Toward Healthcare — Antibody Drug Conjugate Market to Reach USD 32.66 Bn by 2035 (2026): https://www.towardshealthcare.com/insights/antibody-drug-conjugate-market-sizing

7. Grand View Research — Antibody Drug Conjugates Market Size, Top Share, Demand: https://www.grandviewresearch.com/industry-analysis/antibody-drug-conjugates-market

8. WuXi XDC — Addressing Bioconjugates Production Challenges and Accelerating Drug Development (Dec 2024): https://wuxixdc.com/addressing-bioconjugates-production-challenges-and-accelerating-drug-development/

9. Parexel — Challenges and best practices for developing Antibody-Drug Conjugates (ADCs): https://www.parexel.com/insights/blog/challenges-and-best-practices-for-developing-antibody-drug-conjugates-adcs-1

10. APC — Biologics in FDA's 2025 Approvals: Implications for Future CMC Strategies: https://approcess.com/blog/biologics-in-fdas-2025-approvals-implications-for-future-cmc-strategies

11. Quality Executive Partners — ADCs Unleashed: Navigating Development Hurdles in Targeted Cancer Therapy (2025): https://www.qualityexecutivepartners.com/press/adcs-unleashed-navigating-development-hurdles-in-targeted-cancer-therapy

#ADC  #AntibodyDrugConjugates  #CMC  #Oncology  #DrugDevelopment  #Biotech  #Pharma  #CDMO  #RegulatoryStrategy  #Manufacturing  #ClinicalDevelopment  #Pharmefex